MaxCyte, Inc. (MXCT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $1.73M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $2.77M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $1.73M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $1.73M |
| Deferred revenue · latest quarter (USD) | $2.77M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $2.46M + $302.00K ≈ $2.77M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $0.00 | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $302.00K − $302.00K ≈ $0.00 |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 25.92M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 1.73M USD | Accounts Payable, Current |
| Total deferred revenue | 2.77M USD | Contract with Customer, Liability · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | 2.46M USD | Deferred Revenue, Current |
| Deferred revenue due after one year | 302.00K USD | Deferred Revenue, Noncurrent · Contract with Customer, Liability · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 302.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 302.00K USD | Contract with Customer, Liability · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $0.00
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $17.25M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.73M | $2.77M | (m) | $0.00 | $25.92M | (m) | $2.46M | $302.00K | $302.00K | $302.00K |
| 2026-03-31 | (m) | $1.20M | $3.53M | (m) | $0.00 | $26.59M | (m) | $3.27M | $262.00K | $262.00K | $262.00K |
| 2025-12-31 | (m) | $1.40M | $3.86M | (m) | $0.00 | $31.02M | (m) | $3.60M | $263.00K | $263.00K | $263.00K |
| 2025-09-30 | (m) | $1.29M | $5.42M | (m) | $0.00 | $33.20M | (m) | $5.20M | $227.00K | $227.00K | $227.00K |
| 2025-06-30 | (m) | $1.21M | $2.89M | (m) | $0.00 | $29.03M | (m) | $2.64M | $248.00K | $248.00K | $248.00K |
| 2025-03-31 | (m) | $2.28M | $4.42M | (m) | $0.00 | $30.55M | (m) | $4.14M | $270.00K | $270.00K | $270.00K |
| 2024-12-31 | (m) | $1.36M | $5.53M | (m) | $0.00 | $33.22M | (m) | $5.25M | $274.00K | $274.00K | $274.00K |
| 2024-09-30 | (m) | $1.86M | $6.93M | (m) | $0.00 | $35.31M | (m) | $6.65M | $277.00K | $277.00K | $277.00K |
| 2024-06-30 | (m) | $953.00K | $3.68M | (m) | $1.00K | $30.23M | (m) | $3.37M | $309.00K | $310.00K | $309.00K |
| 2024-03-31 | (m) | $1.67M | $4.75M | (m) | $0.00 | $31.57M | (m) | $4.48M | $279.00K | $279.00K | $279.00K |
| 2023-12-31 | (m) | $743.00K | $5.35K | (m) | $5.35M | $36.11M | (m) | $5.07M | $-5.06M | $283.00K | $-5.06M |
| 2023-09-30 | (m) | $446.60K | $5.90M | (m) | $1.00M | $33.35M | (m) | $5.59M | $314.10K | $1.32M | $314.10K |
| 2023-06-30 | (m) | $1.60M | $5.00M | (m) | $1.00M | $30.22M | (m) | $4.69M | $307.40K | $1.31M | $307.40K |
| 2023-03-31 | (m) | $3.50M | $6.10M | (m) | $958.20K | $33.73M | (m) | $5.75M | $350.80K | $1.31M | $350.80K |
| 2022-12-31 | (m) | $531.80K | $7.04M | (m) | $998.50K | $32.69M | (m) | $6.71M | $323.10K | $1.32M | $323.10K |
| 2022-09-30 | (m) | $2.09M | $6.60M | (m) | (m) | $31.98M | (m) | $6.29M | $344.60K | (m) | $0.00 |
| 2022-06-30 | (m) | $2.46M | $7.70M | (m) | $3.60K | $32.55M | (m) | $7.31M | $389.40K | $393.00K | $389.40K |
| 2022-03-31 | (m) | $4.37M | $7.30M | (m) | $-17.20K | $28.77M | (m) | $6.83M | $468.30K | $451.10K | $468.30K |
| 2021-12-31 | (m) | $1.82M | $7.20M | (m) | $0.00 | $21.22M | (m) | $6.75M | $450.20K | $450.20K | $450.20K |
| 2021-09-30 | (m) | $723.30K | $6.80M | (m) | $22.40K | $13.57M | (m) | $6.33M | $474.20K | $496.60K | $474.20K |
| 2021-06-30 | (m) | $644.70K | $7.10M | (m) | $839.80K | $14.33M | (m) | $6.75M | $345.20K | $1.19M | $345.20K |
| 2020-12-31 | (m) | $890.20K | $5.00M | (m) | $631.80K | $18.55M | (m) | $4.84M | $157.00K | $788.80K | $157.00K |
| 2019-12-31 | (m) | (m) | $3.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $2.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |